Review

Does It Really Pay-Off? Comparison of Lymphadenectomy versus Observational Approach in Skin Melanoma with Positive Sentinel Node Biopsy: Systematic Review and Meta-Analysis

Karolina Richter 1, Tomasz Stefura 2,3,*, Krzysztof Macheta 1, Jonasz Tempski 1, Jakub Kazoń 1, Magdalena Szeremeta 1, Paweł Klimont 1, Marta Kołodziej-Rzepa 1,2, Tomasz Wojewoda 1,2 and Wojciech M. Wysocki 1,2,4,*

1 Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Gustawa Herlinga-Crudzińskiego 1, 30-705 Krakow, Poland; karolinaa.richter@gmail.com (K.R.); kmacheta9@gmail.com (K.M.); jonasz.tempski@op.pl (J.T.); kuba0185@wp.pl (J.K.); m.szeremeta.23@gmail.com (M.S.); leon.klimont@gmail.com (P.K.); mar.2.ta@wp.pl (M.K.-R.); wojtom67@gmail.com (T.W.)
2 Department of General, Oncological and Vascular Surgery, 5th Military Clinical Hospital in Kraków, 30-705 Krakow, Poland; tomasz.stefura@gmail.com
3 Department of Medical Education, Faculty of Medicine, Jagiellonian University Medical College Kraków, 30-688 Krakow, Poland
4 Scientific Editorial Office, Maria Skłodowska-Curie Memorial, National Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland
* Correspondence: wwysocki@mp.pl

Abstract: The aim of this meta-analysis was to answer the question as to whether performing CLND (complete lymph node dissection) is necessary in every case of the melanoma patient after the positive SNB (sentinel node biopsy). To resolve doubts the authors reanalyzed previous articles and systematized the knowledge about the concerning medical problem. The databases such as PubMed, Scopus and Web of Science were screened to find articles that will be helpful to answer the controversial question if performing lymphadenectomy is crucial. The inclusion criteria consisted of randomized clinical trials, comparison of lymphadenectomy versus observation and positive sentinel node biopsy. After which, seven articles were examined. Authors analyzed parameters such as: recurrence, 3-year survival and 5-year survival. There was no relationship between the performance of CLND and melanoma recurrence (OR 1.04; 95% CI: 0.82–1.31; \( p = 0.75 \)). However, no CLND group had higher 3-year survival (OR 1.22; 95% CI: 1.03–1.44; \( p = 0.02 \)) and 5-year survival (OR 1.30; 95% CI: 1.19–1.85; \( p = 0.008 \)). In conclusion, the observational approach to the melanoma patients with positive sentinel node biopsy is associated with comparable or slightly improved 3- and 5-year survival, then in case of routine lymphadenectomy. Although, in each melanoma patient a decision to perform or withhold lymphadenectomy should always be considered individually. Patients with low perioperative risk could be considered for surgical approach. The study was registered in PROSPERO and was assigned with the unique identifying number “CRD42021241272”.

Keywords: melanoma; sentinel node biopsy; complete lymph node dissection; lymphadenectomy; meta-analysis

1. Introduction

According to the definition, melanoma is a malignant neoplasm originating from melanocytes dispersed in the skin, mucosa and other organs. Recently there has been a rapid increase in worldwide incidence of new melanoma cases reaching 132,000 globally each year [1].
Early melanoma management for over last two decades included wide surgical excision with clear histological margins followed by examination of the sentinel node (the first draining lymph node to be affected by metastatic disease) to detect clinically occult disease. In sentinel lymph node positive cases, completion lymph node dissection (CLND) was performed as a standard of care. Nevertheless, two major studies published recently, which led to the update of the current guidelines, showed a lack of up-front CLND efficacy as compared to ultrasonographic observation of axilla [2–5].

The current management of melanoma is based on the patient’s qualification for a sentinel node biopsy (SNB). Patients qualified for SNB are patients who: have excision biopsy and have histopathologic confirmation of melanoma, do not show clinical signs of both distant and regional metastases, with Breslow \( \geq 0.8 \) mm or with ulceration on the lesion surface, regardless of the Breslow parameter. In some cases of pT1b melanomas with a thickness of 0.8–1.0 mm, when unfavorable prognostic factors coexist, SNB can be performed without relying on previous criteria [6]. According to NICE 2022 and ESMO 2020 guidelines SNB should be considered in staging of >1.0 mm Breslow thickness in melanoma of AJCC8 stage pT2a, IB, IIC or higher. Melanomas of AJCC8 stage pT1b, with any of the risk factors such as ulceration or high mitotic rate, are questionable—SNB should be taking under advisement [7,8].

The purpose of this meta-analysis was to provide a high-quality and most up-to-date comparison of lymphadenectomy and observational approach in melanoma. In addition to the previous meta-analyses, we designed our search strategy wider, to include all possibly relevant studies published so far and to systematize available knowledge.

2. Materials and Methods

The study was designed to compare two therapeutic options in melanoma patients with positive sentinel lymph node biopsy (SLNB): CLND vs. observation. This systematic review and meta-analysis has been registered in PROSPERO, and was assigned with the unique identifying number “CRD42021241272” [9]. Ethical approval and the informed consent of the participants are not required in systematic reviews with meta-analysis.

2.1. Search Terms

The authors followed the PRISMA guidelines to obtain the highest quality of the work (Supplementary Materials) [10]. The search was conducted using PubMed, Scopus and Web of Science databases and it was limited to studies published between 1995 and 2021. The search strategy was based on following terms: “melanoma”, “malignant melanoma”, “lymphadenectomy”, “complete lymph node dissection”, “sentinel node biopsy”, “positive sentinel node biopsy”, “lymphatic metastasis”, “randomized controlled trial”, “humans” and “compared with”. All above mentioned terms were combined using operators such as “AND” and “OR”. All found abstracts were screened for inclusion by members of the review team (KR, KM, JT, JK, MS and PK), supervised by senior authors (TS, MKR, TW and WMW). Selected abstracts were assessed profoundly and included in meta-analysis correspondingly to the inclusion criteria.

2.2. Eligibility Assessment

The authors conducted an eligibility assessment for all the full-text articles that were filtered during the abstract screening process. We have included randomized clinical trials that reported the treatment of melanoma patients with positive sentinel node biopsy and compared the complete lymph node dissection versus observational approach (i.e., surgery vs. no surgery). Furthermore, the articles had to be written in English. The authors excluded all meta-analyses, systematic reviews and otherwise irrelevant studies.
2.3. Data Extraction

Six reviewers recorded relevant data from included manuscripts. At least two authors extracted data from each article. If any conflicting data occurred, the study was subjected to further discussion with one of senior authors.

2.4. Outcomes of Interest

Data were isolated from included studies: first author, publication year, title, type of the study, country, follow up in months, sex, mean or median age and sample; sample divided into groups: CLND and no CLND; tumor location: head, trunk, extremities, ulceration, Breslow depth, deaths and recurrence; HR: 3-year survival, disease free survival, 5-year survival, melanoma specific survival, overall survival and recurrence free survival.

2.5. Quality Assessment

Quality of the included articles was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB 2). There were several parameters that were measured, such as: “Randomization process”, “Deviations from the intended interventions”, “Missing outcome data”, “Measurement of the outcome” and “Selection of the reported result”. Each article was assessed as “high risk”, “low risk” and “some concerns”.

2.6. Statistical Analysis

Statistical analysis was performed using Review Manager 5.4 (The Cochrane Collaboration, 2020, London, UK). The authors analyzed three parameters: recurrence, 3-year survival and 5-year survival, next they divided articles into 3 subgroups. Statistical parameters such as odds ratios (OR) were generated with 95% confidence intervals (CI) and statistical significance reached to 0.05. Heterogeneity of studies was evaluated using I² test and value above 70 constituted considerable heterogeneity. The quality of analyzed works was checked using Cochrane risk-of-bias tool for randomized trials.

3. Results

3.1. Articles Selection

Primary search strategy produced 744 records, after which qualification process followed, as well as elimination of duplicates, resulting in 425 articles, of which 22 datasets met the criteria for full-text review [2,3,11–27]. Finally, seven papers were included in the meta-analysis (Table 1). The details of the process have been stated in the PRISMA flow-diagram (Figure 1).
| First Author, References | Publication Year | Title                                                                 | Study Design | Country | Follow-Up in Months | Sex (% of Women) | Mean or Median Age | Sample (n) | Sample—Clnd | Sample—no Clnd | Tumor Location Head (n) | Tumor Location Head (%) | Tumor Location Trunk (n) | Tumor Location Trunk (%) | Tumor Location Extremities (n) | Ulceration (n) | Ulceration (%) | Breslow [mm] | Deaths (n) | Deaths (%) | Recurrence (n) | Recurrence (%) |
|-------------------------|-----------------|----------------------------------------------------------------------|--------------|---------|---------------------|-----------------|------------------|------------|------------|----------------|--------------------------|--------------------------|-----------------------------|-----------------------------|--------------------------------|----------------|---------------|------------|-------------|------------|----------------|------------------|
| Klemen, N.D. [28]       | 2019            | Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit | retrospective | International | 28.9  | 39  | 54.5  | 953  | 831  | 122  | 126  | 13  | 397  | 42  | 414  | 43  | 120  | 13  | 2.5  | 227  | 28  | 324  | 39  |
| Bamboat, Z.M. [29]      | 2014            | Observation after a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma | retrospective | International | 66  | 37.7 | 66  | 495  | 167  | 328  | x  | x  | x  | x  | x  | x  | x  | x  | x  | 260  | 52.5 |
| Lee, D.Y. [30]          | 2016            | Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma | retrospective | USA | 83.1 | 33.3 | 57  | 471  | 375  | 96  | 24  | 22.2 | x  | x  | 49 | 45.4 | x  | x  | x  | x  | x  | x  | x  |
| Leiter, U. [31]         | 2016            | Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial | rct | Germany | 35  | 38.5 | 54  | 473  | 240  | 233 | x  | x  | 247 | 52  | 31  | 13  | 95  | 41  | x  | 44  | 14  | 67  | 29  |
| Faries, M.B. [4]        | 2017            | Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma | rct | International | 43 | 41.5  | 53  | 1755 | 824  | 931  | 241  | 13.73 | 805  | 45.7 | 709  | 40.4 | 894  | 50.9 | x  | x  | x  | x  |
| van der Ploeg, A.P.T. [32]| 2012         | Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection | retrospective | International | 34  | 47.5  | 55  | 1174 | 1113 | 61  | 154  | 13.1 | 481  | 41  | 526  | 44.8 | 529  | 45.1 | 2.5  | x  | x  | x  | x  |
| Leiter, U. [3]          | 2019            | Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients with Melanoma with Positive Sentinel Node | rct | Germany | 72  | x  | 54  | 483  | 242  | 241  | x  | x  | x  | x  | x  | x  | 185 | 38.3 | 2.4  | 133 | 27.5 | 166 | 34.4 |

x—Lack of data in the article.
Identification of studies via databases and registers

Records identified from:
- PubMed (n = 376)
- Scopus (n = 287)
- Web of Science (n = 215)
- Registers (n = 0)

Records removed before screening:
- Duplicate records removed (n = 451)
- Records marked as ineligible by automation tools (n = 0)

Records screened (n = 427)

Records excluded (n = 400)

Reports sought for retrieval (n = 27)

Reports not retrieved (n = 2)

Reports assessed for eligibility (n = 25)

Reports excluded:
- Meta-analysis (n = 5)
- Lack of data (n = 5)
- Patients did not undergo lymphadenectomy (n = 1)
- Review (n = 3)
- Case report (n = 1)
- Comparing only sentinel node biopsy not lymphadenectomy (n = 1)
- Other reason (n = 2)

Studies included in review (n = 7)

Reports of included studies

Figure 1. PRISMA flow-diagram of the study inclusion process.

3.2. Articles Characteristic

Seven articles were included into the statistical analysis [3,4,28–32]. Chosen articles contained patients treated in Europe and USA between 1995 and 2016. We stratified data into three subgroups to assess the following outcomes measures: (1) “Melanoma Recurrence”, (2) “3-year survival” and (3) “5-year survival”.

www.mdpi.com/journal/jcm
3.3. Patients Characteristics

The authors included seven articles and a total group of 5321 patients were analyzed. There were 3711 patients who underwent CLND and 1610 patients in whom further surgery was omitted. Complete datasets for given outcomes measures included in total: 1922 patients for melanoma recurrence, 3403 patients for 3-year survival and 3093 patients for 5-year survival.

3.4. Melanoma Recurrence

Meta-analysis of outcomes presented by Bamboat et al., Klemen et al., and Leiter et al. did not prove a statistically significant relationship between the performance of CLND and melanoma recurrence (OR 1.04; 95% CI: 0.82–1.31; p = 0.75). The results are presented in Figure 2.

3.5. Three-Years Melanoma Survival

The analysis of 3-year overall survival included the three studies (Faries et al., Leiter et al., Van der Ploeg et al.). It revealed a statistically significant difference favoring no CLND approach (OR 1.22; 95% CI: 1.03–1.44; p = 0.02). The results are presented in Figure 3.

3.6. Five-Years Melanoma Survival

Five-years melanoma survival analysis included five articles (Bamboat et al., Klemen et al., Lee et al., van der Ploeg et al. 2012, Leiter et al.). Patients undergoing a no CLND approach had higher odds of overall 5-year survival (OR 1.30; 95% CI: 1.19–1.85; p = 0.008). The results are presented in Figure 4.
3.7. Quality Assessment

There was a low risk for bias in the “Missing outcome data”, “Measurement of the outcome” and “Selection of the reported result” domains. There were some concerns involving the risk of bias in domains “Randomization process” and “Deviations from the intended interventions”. The quality of the included articles is presented in Figure 5.

![Quality assessment—Cochrane risk-of-bias tool for randomized trials (RoB 2) [3,4,28–32].](image)

4. Discussion

In the past, melanoma patients have routinely undergone elective dissection of the lymph nodes, which was associated with all variety of well-known potential complications [33]. In case of performing CLND we can expect occurrence of lymphorrhoea, sensory disturbances and lymphoedema [34]. Prophylactic lymphadenectomy is not recommended due to lack of the therapeutic benefit. It can be considered in the presence of lymph node metastases to avoid further dissemination of the disease and to achieve locoregional control. Patients with a tumor diameter <0.1 mm should not undergo routine lymphadenectomy, whereas tumor-diameter of 0.1 mm and 1 mm and above, a total lymphadenectomy may be offered. [35]. Nowadays according to NICE 2022 guidelines therapeutic CLND should be performed in melanoma patients with clinical stage IIIB-IIIC or in any patient that has nodal changes detected in imaging tests [7]. The ESMO 2020 guidelines also support these
recommendations [8]. According to German guidelines, the risk of a positive sentinel node correlates with the presence of ulcers, tumor size and a high rate of mitosis. [35]

One of the most important concepts that changed the therapeutic approach of patients with melanoma was the introduction of sentinel node biopsy prior to lymphadenectomy, which nowadays is the standard of care [14,36,37]. The SNB is a key element in planning the therapeutic procedure—it determines the need for lymphadenectomy, qualification for adjuvant treatment after the procedure and allows for the control of disease advancement in regional lymph nodes [6,36–39].

The aim of our metanalysis was to assess, whether lymphadenectomy should be performed in every case of melanoma patient with positive sentinel node biopsy. After many years, without an unequivocal answer, studies were designed to reanalyze this issue. The value of our pooled study consists in scrupulous analysis of a large group of relevant studies and integrating them in such a way as to draw a unified conclusion. Furthermore, search strategy was wider as compared to previously attempted pooling of data [14,15,17,18,23,40].

According to our results there was no statistically significant difference between CLND and noCLND groups in terms of melanoma recurrence. Nevertheless, when analyzing the 3-year and 5-year survival outcomes favored the group in which the lymphadenectomy was not performed. Additionally, Breit et al., after analyzing works of other authors, suggests that performing a lymphadenectomy does not increase melanoma specific survival compared to patients in whom lymphadenectomy was abandoned [4,12,31,33,40,41]. The study of Standage (2019) showed that observational approach is the most efficient from among therapeutic options in melanoma patients with positive SNB. The advantage of the observational approach over lymphadenectomy results not only from the greater benefits for the patient’s quality of life, higher 3- and 5-year survival, but also from the lower costs [42].

There are several potential sources of heterogeneity in this study. Although the study design and data collection was conducted correctly there is a risk of high heterogeneity of the study group which can form a problem when comparing parameters. The observed variability is due to differences at the clinical level of melanoma—in included studies there was no division into types of recurrence (locoregional or distal).

When making decisions concerning CLND, all circumstances should be considered, especially the potential benefits for the patients and potential risks associated with surgery [14]. However, if a lymphadenectomy is not performed, the patient should be monitored using ultrasonography of regional lymph nodes every 3–4 months, which requires high level of compliance [35,43,44].

5. Conclusions

Therefore, in each case the decision to perform or withhold lymphadenectomy in patients with melanoma and a positive sentinel node, should be considered individually and taken after profound discussion with the patient. The observational approach to the melanoma patients with positive sentinel node biopsy is associated with comparable or even slightly improved survival. Patients with low perioperative risk could be still considered for surgical approach, particularly if no strict clinical follow-up is available to them.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11133880/s1.

Author Contributions: Conceptualization Study Design: T.S. and W.M.W.; Data Collection: K.R., T.S., K.M., J.T., J.K., M.S. and P.K.; Statistical Analysis: K.R., T.S., K.M. and W.M.W.; Data Interpretation: K.R., T.S., K.M., J.T., M.K.–R., T.W. and W.M.W.; Manuscript Preparation: K.R., T.S., K.M. and W.M.W.; Literature Search: K.R., T.S., K.M., J.T., J.K., M.S. and P.K. All authors have read and agreed to the published version of the manuscript.
Funding: Research grant funded by Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzyewski Krakow University, Gustawa Herlinga-Grudzińskiego 1, 30-705 Kraków.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Available online: https://www.who.int/news-room/q-a-detail/radiation-ultraviolet-(uv)-radiation-and-skin-cancer (accessed on 24 March 2021).
2. Delgado, A.F. Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta-Analysis. Anticancer Res. 2017, 37, 6825–6829. [PubMed]
3. Leiter, U.; Standard, R.; Mauch, C.; Hohenberger, W.; Brocker, N.H.; Berking, C. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients with Melanoma with Positive Sentinel Node. J. Clin. Oncol. 2019, 37, 3000–3008. [CrossRef] [PubMed]
4. Faries, M.B.; Thompson, J.F.; Cochran, A.J.; Andtbacka, R.H.; Mozzillo, N.; Zager, J.S. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N. Engl. J. Med. 2017, 376, 2211–2222. [CrossRef] [PubMed]
5. Available online: https://www.mp.pl/paim/issue/article/15936/ (accessed on 30 March 2021).
6. Rutkowski, P.; Wysoki, P.; Nasierowska-Guttmejer, A. Cutaneous melanomas. Oncol. Clin. Pract. 2019, 15, 163–182. [CrossRef]
7. National Collaborating Centre for Cancer (UK). Melanoma: Assessment and Management; National Institute for Health and Care Excellence (NICE): London, UK, 2015.
8. Michielin, O.; van Akkooi, A.; Lorigan, P.; Asciento, P.A.; Dummer, R.; Robert, C.; Arance, A.; Blank, C.U.; Sileni, V.C.; Donia, M.; et al. ESMO consensus conference recommendations on the management of locoregional melanoma: Under the auspices of the ESMO Guidelines Committee. Ann. Oncol. 2020, 31, 1449–1461. [CrossRef]
9. PROSPERO International Prospective Register of Systematic Reviews. Complete Lymph Node Dissection vs. Observation of Sentinel Lymph Node-Positive Melanoma Patients; University of York: Harlow, UK, 2017.
10. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [CrossRef]
11. Guggenheim, M.M.; Hug, U.; Jung, F.J.; Rousson, V.; Aust, M.C.; Calcagni, M. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann. Surg. 2008, 247, 687–693. [CrossRef]
12. Bartlett, E.K.; Lee, A.Y.; Spanheimer, P.M.; Bello, D.M.; Brady, M.S.; Ariyan, C.E. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma. Br. J. Surg. 2020, 107, 1480–1488. [CrossRef]
13. Downs, J.S.; Gyorki, D.E. An evidence-based approach to positive sentinel node disease: Should we ever do a completion node dissection? Melanoma Manag. 2019, 6, MMT24. [CrossRef]
14. Macedo, E.I.; Fayne, R.A.; Azab, B.; Yakoub, D.; Möller, M.G. The Role of Completion Lymphadenectomy in Positive Regional Lymph Nodes in Melanoma: A Meta-analysis. J. Surg. Res. 2019, 236, 83–91. [CrossRef]
15. Hieken, T.J.; Kane, J.M.; Wong, S.L. The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma. Ann. Surg. Oncol. 2019, 26, 1028–1034. [CrossRef]
16. Affleck, A.G.; Proby, C.M. Completion lymphadenectomy should not necessarily be recommended after a positive sentinel lymph node biopsy. Clin. Exp. Dermatol. 2019, 44, 79–80. [CrossRef] [PubMed]
17. Hewitt, D.B.; Merkow, R.P.; DeLancey, J.O.; Wayne, J.D.; Hyngstrom, J.R.; Russell, M.C. National practice patterns of completion lymph node dissection for sentinel node-positive melanoma. J. Surg. Oncol. 2018, 118, 493–500. [CrossRef] [PubMed]
18. Persa, O.-D.; Knuever, J.; Mauch, C.; Schlaak, M. Complete lymph node dissection or observation in melanoma patients with multiple positive sentinel lymph nodes: A single-center retrospective analysis. J. Dermatol. 2018, 45, 1191–1194. [CrossRef]
19. Hohenberger, W. Survival after radical completion dissection or observation for sentinel node metastasis in melanoma. Strahlenther. Onkol. 2017, 193, 989–990. [CrossRef] [PubMed]
20. Fioranelli, M.; Roccia, M.G.; Pastore, C.; Aracena, C.; Lotti, T. Completion dissection or observation for sentinel-node metastasis in melanoma. Dermatol. Ther. 2017, 30, e12544. [CrossRef] [PubMed]
21. Mosquera, C.; Vora, H.S.; Vohra, N.; Fitzgerald, T.L. Population-Based Analysis of Completion Lymphadenectomy in Intermediate-Thickness Melanoma. Ann. Surg. Oncol. 2016, 23, 127–134. [CrossRef] [PubMed]
22. Morton, D.L.; Thompson, J.F.; Cochran, A.J.; Mozzillo, N.; Nieweg, O.E.; Roses, D.F. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 2014, 370, 599–609. [CrossRef]
23. Nagaraja, V.; Eslick, G.D. Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis. Eur. J. Surg. Oncol. 2013, 39, 669–680. [CrossRef]
24. Van der Ploeg, A.P.T.; van Akkoori, A.C.J.; Verhoef, C.; Eggermont, A.M.M. Completion lymph node dissection after a positive sentinel node: No longer a must? Curr. Opin. Oncol. 2013, 25, 152–159. [CrossRef]

25. Elias, N.; Tanabe, K.K.; Sober, A.J.; Gadd, M.A.; Mihm, M.C.; Goodspeed, B. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Arch. Surg. 2004, 139, 400–404. [CrossRef] [PubMed]

26. Burke, E.E.; Portschy, P.R.; Tuttle, T.M.; Kuntz, K.M. Completion Lymph Node Dissection or Observation for Melanoma Sentinel Lymph Node Metastases: A Decision Analysis. Ann. Surg. Oncol. 2016, 23, 2772–2778. [CrossRef] [PubMed]

27. Wong, S.L.; Morton, D.L.; Thompson, J.F.; Gershewald, J.E.; Leong, S.P.L.; Reintgen, D.S. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study. Ann. Surg. Oncol. 2006, 13, 809–816. [CrossRef]

28. Klemen, N.D.; Han, G.; Leong, S.P.; Kashani-Sabet, M.; Vetto, J.; White, R. Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. J. Surg. Oncol. 2019, 119, 1053–1059. [CrossRef] [PubMed]

29. Bamboat, Z.M.; Konstantinidis, I.T.; Kuk, D.; Ariyan, C.E.; Brady, M.S.; Coit, D.G. Observation after a positive sentinel lymph node biopsy in patients with melanoma. Ann. Surg. Oncol. 2014, 21, 3117–3123. [CrossRef]

30. Lee, D.Y.; Lau, B.J.; Huynh, K.T.; Flaherty, D.C.; Lee, J.-H.; Stern, S.L. Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma. J. Am. Coll. Surg. 2016, 223, 9–18. [CrossRef]

31. Leiter, U.; Stadler, R.; Mauch, C.; Hohenberger, W.; Brockmeyer, N.; Berking, C. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): A multicentre, randomised, phase 3 trial. Lancet Oncol. 2016, 17, 757–767. [CrossRef]

32. Van der Ploeg, A.P.T.; van Akkooi, A.C.J.; Rutkowski, P.; Cook, M.; Nieweg, O.E.; Rossi, C.R. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. Br. J. Surg. 2012, 99, 1396–1405. [CrossRef]

33. Landry, C.S.; McMasters, K.M.; Scoggins, C.R. The evolution of the management of regional lymph nodes in melanoma. J. Surg. Oncol. 2007, 96, 316–321. [CrossRef]

34. Piekarski, J. Should a completion lymphadenectomy be performed after a positive biopsy of the sentinel node in melanoma? A vote for “no”. Nowotw. J. Oncol. 2019, 69, 71–74. [CrossRef]

35. Guideline Program Oncology (German Cancer Society, German Cancer Aid, AWMF): Diagnosis, Therapy and Aftercare of Melanoma, Long Version 3.3, 2020, AWMF Register Number: 032/024OL. Available online: https://www.leitlinienprogramm-onkologie.de/leitlinien/melanom/ (accessed on 3 June 2022).

36. Carlson, G.W.; Murray, D.R.; Lyles, R.H.; Staley, C.A.; Hestley, A.; Cohen, C. The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance? Ann. Surg. Oncol. 2003, 10, 575–581. [CrossRef] [PubMed]

37. Reeves, M.E.; Delgado, R.; Busam, K.J.; Brady, M.S.; Coit, D.G. Prediction of nonsentinel lymph node status in melanoma. Ann. Surg. Oncol. 2003, 10, 27–31. [CrossRef] [PubMed]

38. Wagner, J.D.; Ranieri, J.; Evdokimov, D.Z.; Logan, T.; Chuang, T.-Y.; Johnson, C.S. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Am. J. Surg. 2016, 212, 686–688. [CrossRef] [PubMed]

39. Gonzalez, A. Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis. Am. J. Clin. Dermatol. 2018, 19, 24–30. [CrossRef] [PubMed]

40. Angeles, C.V.; Kang, R.; Shirai, K.; Wong, S.L. Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma. Br. J. Surg. 2019, 106, 672–681. [CrossRef]

41. Breit, S.; Foley, E.; Ablah, E.; Okut, H.; Mammen, J. Recent Evolution in the Management of Lymph Node Metastases in Melanoma. J. Surg. Oncol. 2021, 2913–2922. [CrossRef]

42. Standage, H.; Hersh, A.R.; Coughlin, A. What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node? Ann. Surg. Oncol. 2021, 28, 1464–1468. [CrossRef]

43. Landry, C.S.; McMasters, K.M.; Scoggins, C.R. The evolution of the management of regional lymph nodes in melanoma. Plast. Reconstr. Surg. 2003, 112, 486–497. [CrossRef] [PubMed]

44. Gonzalez, A. Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis. Am. J. Clin. Dermatol. 2018, 19, 24–30. [CrossRef] [PubMed]

45. Angeles, C.V.; Kang, R.; Shirai, K.; Wong, S.L. Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma. Br. J. Surg. 2019, 106, 672–681. [CrossRef]

46. Breit, S.; Foley, E.; Ablah, E.; Okut, H.; Mammen, J. Recent Evolution in the Management of Lymph Node Metastases in Melanoma. J. Surg. Oncol. 2021, 2913–2922. [CrossRef]

47. Standage, H.; Hersh, A.R.; Coughlin, A. What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node? Ann. Surg. Oncol. 2021, 28, 2913–2922. [CrossRef]

48. Wysocki, W.M.; Rutkowski, P. Management of metastases in regional lymph nodes in melanoma patients in 2019. Nowotw. J. Oncol. 2019, 69, 108–110. [CrossRef]

49. Wysocki, W.M.; Grela-Wojewoda, A.; Jankowski, M. Fallen dogmas: Recent advances in locoregionally advanced melanoma. Pol. Arch. Intern. Med. 2021, 131, 464–468. [CrossRef]